Litigation Finance, Royalties, and Other Uncommon Assets

Specialty assets are the strategies that fit no other bucket — litigation finance, royalty streams, equipment leasing, life settlements, and structured notes. Each generates return from something with little connection to the stock market. A jury verdict, a catalog's streaming volume, and a mortality table have nothing to do with corporate earnings multiples. Non-correlation is the appeal; opacity is the price.

The label is a residual — the only thing it tells you is that the strategy is unusual. Two offerings both called specialty assets can have nothing in common: one a pool of non-recourse legal funding, the other a bank-issued note tracking an equity index. Each has to be underwritten on its own mechanics, not as a category allocation.

Litigation finance: funding lawsuits

A litigation finance fund advances the cost of pursuing legal claims for a share of any recovery, generally non-recourse — if the case loses, the funder receives nothing. Returns depend on case outcomes and timing — a court calendar does not care what equities did. The risks are binary outcomes and unpredictable duration: a case expected to settle in a year can grind on for several, compressing the result even on a win.

Royalties: a share of usage revenue

A royalty strategy buys a share of the revenue an underlying asset produces — a music catalog, a pharmaceutical patent, a mineral interest — so the return is driven by usage: streams played, prescriptions filled. That independence puts all the weight on one question: does the stream hold up or decay? A catalog can fade, a drug can face generic competition at patent expiry. This is a bet on continued demand, not a bond with a different name.

Equipment leasing: hardware on lease

An equipment leasing fund buys hardware — trailers, containers, industrial equipment — and leases it to operators, earning lease payments plus whatever the equipment is worth at the end. Each piece carries its own risk: the payments depend on the lessee's credit, the residual on a resale market that may have moved or been disrupted by newer technology.

Life settlements: buying unwanted policies

A life settlement fund buys policies from insureds who no longer want them — more than the surrender value, less than the face amount — then carries the premiums and collects the death benefit. The return turns on actual mortality against the underwriting estimate and on the cost of carrying premiums, so the central risk is longevity: each extra year of life adds outlay and delays the payoff. Some investors object to the structure on its own terms, which is a legitimate reason to pass.

Structured notes: a payoff built by a bank

A structured note is bank-issued debt whose return is linked to something else — an index, a basket of stocks, a rate — usually with engineered features: a buffer that absorbs an initial portion of a decline, a cap that limits the upside. That lets you shape a payoff to a specific view. A note is only as sound as the bank that issues it, so issuer creditworthiness is part of the investment. And a note linked to an equity index is equity risk in a different shape — useful, but not a diversifier.

Correlation is what hurts you in a downturn: when everything you own falls together, the only source of cash is selling something you did not want to sell. An asset whose return depends on litigation outcomes, lease payments, or royalty streams keeps doing its own work regardless of what equities did that quarter — and that independence, when genuine, is the most valuable property a diversifier can have.

Some non-correlation is economic and some is a measurement artifact. A royalty stream is genuinely independent of the S&P. An illiquid asset marked once a quarter can appear uncorrelated because it is never priced during a selloff — an asset that is not marked cannot correlate with anything. Before crediting a strategy with diversification, ask whether the independence sits in the cash flows or in the reporting frequency.

Opacity is the price of the genuine article. Disclosure here is less standardized than in public securities, and the payoffs take work to understand. You are relying on the manager's model — mortality tables, case-outcome probabilities, residual value curves — which you cannot verify, so the manager's track record carries more weight here than anywhere else. One test I would not compromise on: if you cannot explain in plain language how a strategy makes and loses money, you do not understand it well enough to fund it.

Consider an investor whose diversified mix of stocks and bonds nearly all moves together in a sharp sell-off. A specialty allocation — say, a structured note with a downside buffer paired with a royalty strategy — is aimed at that gap, and the two pieces do different jobs despite sharing a category label.

The note returns a defined payoff tied to an index, with a buffer that trades away some upside to pay for downside protection. The royalty strategy pays income based on usage, regardless of market conditions. Neither depends on equities rising, but only one is genuinely non-correlated: the note's payoff is a function of the index it references, so it reshapes equity risk rather than removes it; the royalty income has no equity link at all.

The note carries the issuing bank's credit risk — if the issuer fails, the buffer means nothing, because a buffer is a contractual promise from a balance sheet. The royalty strategy is illiquid, with no secondary market, and the features that create the note's protection also cap its gains. The role is diversification and defined outcomes rather than maximum return.

Specialty assets are a finishing allocation, not a foundation: they make sense once a portfolio has a core and a clear picture of what it leaves exposed — a specific gap, not a general wish for something different. Size them small enough that any single strategy failing outright is absorbable, because the failure modes here are unusual: a change in how courts treat litigation funding, a technology shift that guts a residual value assumption, a bank downgrade. Those are not risks a diversified portfolio otherwise carries — both the point and the problem.

The other reason to keep positions modest is that diligence does not scale: each strategy requires understanding a different industry, so holding four means four research obligations that share nothing. I would rather see one strategy genuinely understood than four held on faith — where the model cannot be verified, the people running it are the investment. Portfolio construction is where you work out which gap you are filling.

The category rewards an investor willing to do the work to understand something unusual, and equally willing to walk away when the explanation does not hold together. Complexity is often where the return lives, because it is what keeps most capital away. But complexity you have not resolved is not an opportunity — it is an unpriced risk.